pericalline: alkaloid isolated from Catharanthus trichophyllus roots; active against experimental neoplasm; RN in Chemline for (-)-isomer: 2122-36-3 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Catharanthus | genus | A plant genus of the family Apocynaceae. It is the source of VINCA ALKALOIDS, used in leukemia chemotherapy.[MeSH] | Apocynaceae | The dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH] |
| Catharanthus trichophyllus | species | [no description available] | Apocynaceae | The dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 6436240 |
| CHEMBL ID | 486306 |
| MeSH ID | M0052990 |
| Synonym |
|---|
| nsc 85631 |
| 4-ethylidene-1,3,4,5,6,7-hexahydro-6-methylene-2,5-ethano-2h-azocino(4,3-b)indole |
| pericalline |
| 3463-93-2 |
| (e)-ethylidene(methylene)[?] |
| 2,5-ethano-2h-azocino[4,3-b]indole, 4-ethylidene-1,3,4,5,6,7-hexahydro-6-methylene-, (4e,5r)- |
| apparicine, gomezine, pericalline, tabernoschizine |
| CHEMBL486306 |
| bdbm50480310 |
| (13s,14e)-14-ethylidene-12-methylidene-1,8-diazatetracyclo[11.2.2.03,11.05,9]heptadeca-3(11),4,6,9-tetraene |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID397122 | Inhibition of HIV1 RT | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.28) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||